Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm





    Chief Complaint


    Organ System


    Patent Pending

    Fibrosis-4 (FIB-4) Index for Liver Fibrosis

    Noninvasive estimate of liver scarring in HCV and HBV patients, to assess need for biopsy.
    When to Use
    Why Use
    • Patients with any known risk factors for liver disease, including chronic hepatitis, alcoholic liver disease, non-alcoholic fatty liver disease (NAFLD) and the cholestatic and metabolic liver diseases.
    • Patients with known liver fibrosis should have their fibrosis trended over time to evaluate for progression or stabilization.
    • Liver fibrosis often progresses non-linearly, so it is important to be able to re-assess fibrosis trends in individual patients over time, and invasive re-assessments carry significant risk to patients. FIB-4 allows for non-invasive liver fibrosis assessment.
    • FIB-4 was developed in patients with HIV and HCV co-infection.
    • FIB-4 was developed to correlate with Ishak levels of fibrosis (by biopsy) with 3 levels:
      • 0-2 (mild fibrosis)
      • 3-4 (moderate fibrosis)
      • 5-6 (severe fibrosis/cirrhosis)
    • While liver biopsy is the gold standard for the diagnosis of liver fibrosis, it is not ideal; biopsy only evaluates a minute portion of the liver itself, so sampling errors can occur. Liver biopsy also comes with substantial morbidity.
    • Liver fibrosis often progresses non-linearly, so it is important to be able to re-assess fibrosis trends in individual patients over time.
    • It is critical that tests to identify liver cirrhosis are highly sensitive, as patients with the disease require screening for hepatocellular carcinoma (HCC) and gastroesophageal varices.


    Please fill out required fields.

    Next Steps
    Creator Insights


    • Low fibrosis scores may be appropriate candidates for medical management and may not require liver biopsy if FIB-4 scores continue to stay low.
    • Severe fibrosis/cirrhosis scores may need liver biopsy for confirmation of cirrhosis unless there are other clinical or imaging signs of progression to end-stage liver disease.


    Fibrosis 4 Score = (Age*AST) / (Platelets*√(ALT))

    Facts & Figures

    • FIB-4 scores <1.45 have a negative predictive value of 90% for advanced fibrosis (meaning minimal amounts of scarring) with 81% sensitivity.
    • FIB-4 scores >3.25 have a positive predictive value of 65% for advanced fibrosis with 97% specificity.
    • The original authors estimate that liver biopsy could have been avoided by using the FIB-4 Score with 86% accuracy.
    Dr. Richard Sterling

    About the Creator

    Richard K. Sterling, MD, is a professor and the chief of hepatology at Virginia Commonwealth University. His research interests include liver transplantation, HIV-HCV coinfection, acute and chronic liver disease, viral hepatitis C and B, and other hepatic pathologies.

    To view Dr. Richard Sterling's publications, visit PubMed